Zentek Ltd.
Fundamentals are temporarily unavailable for ZTEK.
| CAD | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
| Revenue | $72.86K | $29.82K | $872.50K | $166.05K |
| Cost of Revenue | $853.34K | $331.08K | $644.61K | $1.84M |
| Gross Profit | -$780.48K | -$301.26K | $227.88K | -$1.67M |
| Research & Development | $1.65M | $1.78M | $465.65K | $1.65M |
| Selling, General & Admin | $10.99M | $8.95M | $8.01M | $6.27M |
| Operating Expenses | $14.73M | $12.01M | $9.83M | $8.26M |
| Operating Income | -$14.65M | -$11.98M | -$9.60M | -$9.93M |
| EBITDA | -$13.75M | -$11.08M | -$9.35M | -$8.98M |
| Pretax Income | -$14.41M | -$11.80M | -$10.04M | -$9.77M |
| Income Tax | $0.00 | -$99.78K | $0.00 | — |
| Net Income | -$14.41M | -$11.70M | -$10.04M | -$9.77M |
| Diluted EPS | -0.14 | -0.12 | -0.10 | -0.09 |
| Diluted Shares | 99.44M | 100.50M | 102.98M | 105.92M |
| CAD | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
| Cash & Equivalents | $10.36M | $3.52M | $121.48K | $1.30M |
| Receivables | $3.55M | $839.79K | $1.20M | $371.25K |
| Inventory | $2.85M | $1.42M | $887.51K | $417.55K |
| Current Assets | $17.95M | $6.25M | $4.37M | $2.28M |
| Total Assets | $33.29M | $22.59M | $18.40M | $15.09M |
| Current Liabilities | $2.42M | $1.82M | $3.49M | $3.53M |
| Long-Term Debt | — | $259.11K | — | $1.75M |
| Total Debt | $1.61M | $1.24M | $680.47K | $1.91M |
| Total Liabilities | $2.90M | $2.41M | $3.65M | $5.28M |
| Retained Earnings | -$66.20M | -$76.62M | -$83.85M | -$91.22M |
| Shareholders' Equity | $30.38M | $20.17M | $14.75M | $9.80M |
| Working Capital | $15.53M | $4.43M | $882.89K | -$1.26M |
| Net Debt | — | — | $225.27K | $448.58K |
| CAD | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
| Operating Cash Flow | -$12.96M | -$8.05M | -$6.28M | -$5.07M |
| Capital Expenditure | -$2.27M | -$591.96K | -$184.61K | -$701.86K |
| Free Cash Flow | -$15.23M | -$8.64M | -$6.47M | -$5.77M |
| Depreciation & Amortisation | $539.69K | $613.71K | $600.32K | $526.40K |
| Stock-Based Compensation | $3.20M | $1.79M | $1.53M | $1.26M |
| Investing Cash Flow | -$2.31M | $1.88M | $358.65K | $1.67M |
| Financing Cash Flow | -$1.05M | -$665.47K | $2.52M | $4.58M |
| Net Change in Cash | -$16.32M | -$6.84M | -$3.40M | $1.18M |
| CAD | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|---|
| Revenue | $813.60K | $57.80K | $6.20K | $65.28K | $36.77K | $0.00 |
| Cost of Revenue | $267.50K | $30.60K | $3.23K | $90.19K | $1.71M | $0.00 |
| Gross Profit | $546.09K | $27.20K | $2.98K | -$24.91K | -$1.68M | $0.00 |
| Research & Development | $203.30K | $140.79K | $267.91K | $744.62K | $500.07K | $242.03K |
| Selling, General & Admin | $2.13M | $1.35M | $1.84M | $1.75M | $1.34M | $1.39M |
| Operating Expenses | $2.91M | $1.83M | $2.33M | $2.36M | $1.74M | $2.08M |
| Operating Income | -$2.10M | -$1.80M | -$2.32M | -$2.39M | -$3.42M | -$2.08M |
| EBITDA | -$1.88M | -$1.17M | -$2.19M | -$2.29M | -$3.33M | -$1.85M |
| Pretax Income | -$1.84M | -$1.36M | -$2.39M | -$2.49M | -$3.53M | -$2.04M |
| Income Tax | $0.00 | — | — | — | — | — |
| Net Income | -$1.84M | -$1.36M | -$2.39M | -$2.49M | -$3.53M | -$2.04M |
| Diluted EPS | — | -0.01 | -0.02 | -0.02 | — | -0.02 |
| Diluted Shares | — | 104.58M | 104.72M | 106.76M | — | 115.40M |
| CAD | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $121.48K | $2.89M | $1.33M | $1.80M | $1.30M | $16.60M |
| Receivables | $1.20M | $394.43K | $226.22K | $445.29K | $371.25K | $391.78K |
| Inventory | $887.51K | $892.32K | $888.98K | $838.43K | $417.55K | $393.49K |
| Current Assets | $4.37M | $4.53M | $2.75M | $3.32M | $2.28M | $17.60M |
| Total Assets | $18.40M | $18.48M | $16.87M | $17.38M | $15.09M | $30.86M |
| Current Liabilities | $3.49M | $2.80M | $3.48M | $3.33M | $3.53M | $3.79M |
| Long-Term Debt | — | $1.58M | $1.64M | $1.69M | $1.75M | $1.81M |
| Total Debt | $680.47K | $1.88M | $1.89M | $1.90M | $1.91M | $1.93M |
| Total Liabilities | $3.65M | $4.49M | $5.18M | $5.04M | $5.28M | $5.60M |
| Retained Earnings | -$83.85M | -$84.85M | -$87.23M | -$87.70M | -$91.22M | -$92.94M |
| Shareholders' Equity | $14.75M | $13.99M | $11.69M | $12.34M | $9.80M | $25.26M |
| Working Capital | $882.89K | $1.74M | -$730.86K | -$12.01K | -$1.26M | $13.81M |
| Net Debt | $225.27K | — | $303.17K | — | $448.58K | — |
| CAD | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -$1.28M | -$1.17M | -$1.21M | -$1.95M | -$734.92K | -$1.18M |
| Capital Expenditure | -$89.40K | -$53.24K | -$323.24K | -$151.00K | -$174.38K | -$583.02K |
| Free Cash Flow | -$1.37M | -$1.23M | -$1.53M | -$2.10M | -$909.31K | -$1.76M |
| Depreciation & Amortisation | $139.55K | $134.34K | $135.09K | $130.12K | $126.86K | $124.62K |
| Stock-Based Compensation | $279.68K | $121.56K | $69.30K | $530.58K | $534.69K | $401.70K |
| Investing Cash Flow | -$89.40K | $2.31M | -$323.24K | -$151.00K | -$171.36K | -$583.02K |
| Financing Cash Flow | $8.71K | $1.63M | -$22.13K | $2.57M | $407.85K | $17.06M |
| Share Repurchases | — | $0.00 | $0.00 | $0.00 | — | — |
| Net Change in Cash | -$1.36M | $2.77M | -$1.55M | $466.57K | -$498.44K | $15.29M |
Market Snapshot
About
Zentek is a nanotechnology company focused on developing antimicrobial solutions and materials. The company leverages graphene-based nanomaterials for applications in healthcare, consumer products, and industrial sectors. Zentek aims to address challenges in infection control and material performance through advanced nanomaterial technology.